^
BIOMARKER:

CD20 expression

i
Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
Entrez ID:
Related biomarkers:
CD20 expression
NHL
rituximab-arrx
Sensitive: A1 - Approval
CD20 expression
CLL
rituximab-arrx
Sensitive: A1 - Approval
CD20 expression
Childhood B Acute Lymphoblastic Leukemia
rituximab + bortezomib
Sensitive: C3 – Early Trials
CD20 expression
B Acute Lymphoblastic Leukemia
rituximab
Sensitive: C3 – Early Trials
CD20 expression
NHL
REGN1979
Resistant: C3 – Early Trials
CD20 expression
Lymphoma
daratumumab + NKTR-255
Sensitive: C3 – Early Trials
CD20 expression
Lymphoma
NKTR-255 + Ritucad (rituximab biosimilar)
Sensitive: D – Preclinical
CD20 expression
NHL
lenalidomide + GEN3013
Sensitive: D – Preclinical